chloroquine has been researched along with tacrolimus in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Harikishore, A; Leow, ML; Liu, X; Niang, M; Pasunooti, KK; Preiser, PR; Rajan, S; Yoon, HS | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Goos, M; Mertins, K; Nussbaum, G; Ockenfels, HM; Schultewolter, T; Wagner, SN | 1 |
| Bader, S; Forooghian, F; Gilman, A; HayGlass, KT; Hsiao, CC; Rempel, J; Schultz, KR; Su, WN | 1 |
| Bruch-Gerharz, D; Haust, M; Homey, B; Meller, S | 1 |
| Fierlbeck, I; Hartmann, M | 1 |
| Bakardzhiev, I; Chokoeva, AA; Krasnaliev, I; Lotti, T; Tana, C; Tchernev, G; Wollina, U | 1 |
| Herz-Ruelas, ME; Ocampo-Candiani, J; Ocampo-Garza, J | 1 |
1 review(s) available for chloroquine and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for chloroquine and tacrolimus
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Adamantyl derivative as a potent inhibitor of Plasmodium FK506 binding protein 35.
Topics: | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Cells, Cultured; Chloroquine; Cyclosporine; Ethanol; Female; Humans; Immunosuppressive Agents; Irritants; Lithium; Lymphocyte Activation; Male; Middle Aged; Phosphorylation; Phytohemagglutinins; Propranolol; Protein-Tyrosine Kinases; Psoriasis; T-Lymphocytes; Tacrolimus; Time Factors; Tyrosine | 1995 |
Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD.
Topics: Animals; Antigen Presentation; Apoptosis; Cells, Cultured; Chloroquine; Cytokines; Drug Evaluation, Preclinical; Drug Synergism; Everolimus; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Interleukin-2; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Minor Histocompatibility Antigens; Recombinant Proteins; Sirolimus; T-Lymphocytes; Tacrolimus | 2002 |
[Light induced subacute cutaneous lupus erythematodes: diagnosis and management].
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents; Basement Membrane; Chloroquine; Drug Therapy, Combination; Epithelium; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Methylprednisolone; Photosensitivity Disorders; Skin; Tacrolimus | 2007 |
[57-year old female with persistent bilateral oedema of the eyelids. Paraneoplastic dermatomyositis].
Topics: Administration, Topical; Blepharitis; Chloroquine; Dermatomyositis; Female; Humans; Immunosuppressive Agents; Injections, Intravenous; Middle Aged; Paraneoplastic Syndromes; Tacrolimus; Treatment Outcome | 2009 |
Unilateral unique Lupus tumidus: pathogenetic mystery and diagnostic problem.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Biopsy; Chloroquine; Combined Modality Therapy; Dapsone; Diagnosis, Differential; Humans; Hydroxychloroquine; Lasers, Dye; Lupus Erythematosus, Discoid; Male; Ointments; Quinacrine; Skin; Sunscreening Agents; Tacrolimus | 2016 |
Acquired Hyperpigmentation and Cicatricial Alopecia.
Topics: Aged; Alopecia; Chloroquine; Diagnosis, Differential; Female; Humans; Hyperpigmentation; Lichen Planus; Tacrolimus; Treatment Outcome | 2016 |